Drug Modeling Softwares Market, Global Outlook and Forecast 2023-2029
Drug Modeling has become an essential tool in the drug design process. Software based drug discovery and development methods are playing key a role in the development of novel drugs. Software based methods such as molecular modeling, structure-based drug design, structure-based virtual screening, ligand interaction and molecular dynamics are considered to be powerful tool for the investigation of pharmacokinetic and pharmacodynamic properties of drugs. These methods are fast, accurate, and provide valuable insights of experimental findings and mechanisms of action. Additionally, appropriate implementation of these techniques may help in reducing drug designing and development cost.
This report aims to provide a comprehensive presentation of the global market for Drug Modeling Softwares, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drug Modeling Softwares. This report contains market size and forecasts of Drug Modeling Softwares in global, including the following market information:
Global Drug Modeling Softwares Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Drug Modeling Softwares market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Database Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Drug Modeling Softwares include JSR Corporation(Crown Bioscience), Chemical Computing Group ULC, Nimbus Therapeutics, Schrodinger, Inc, Genedata AG, Biognos AB, Compugen Ltd, Dassault Systemes and Acellera, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Drug Modeling Softwares companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Drug Modeling Softwares Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Drug Modeling Softwares Market Segment Percentages, by Type, 2022 (%)
Database
Software
Others
Global Drug Modeling Softwares Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Drug Modeling Softwares Market Segment Percentages, by Application, 2022 (%)
Drug Discovery and Development
Computational Physiological Medicine
Disease Modelling
Medical Imaging
Predictive Analysis of Drug Targets
Simulation Software
Cellular Simulation
Others
Global Drug Modeling Softwares Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Drug Modeling Softwares Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Drug Modeling Softwares revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Drug Modeling Softwares revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
JSR Corporation(Crown Bioscience)
Chemical Computing Group ULC
Nimbus Therapeutics
Schrodinger, Inc
Genedata AG
Biognos AB
Compugen Ltd
Dassault Systemes
Acellera
Instem(Leadscope)
Outline of Major Chapters:
Chapter 1: Introduces the definition of Drug Modeling Softwares, market overview.
Chapter 2: Global Drug Modeling Softwares market size in revenue.
Chapter 3: Detailed analysis of Drug Modeling Softwares company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Drug Modeling Softwares in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
